2019
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2018
A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)
Conway B, Dore G, Altice F, Litwin A, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT). Journal Of The Canadian Association Of Gastroenterology 2018, 1: 299-300. PMCID: PMC6508009, DOI: 10.1093/jcag/gwy008.173.Peer-Reviewed Original ResearchEnd of treatmentImmediate treatment groupHCV reinfectionProbable reinfectionHCV RNATreatment groupsLong-term response ratesHepatitis C virus genotypesEBR/GZRHCV reinfection ratesUndetectable HCV RNARisk of reinfectionC virus genotypesInterferon-free HCV treatmentRate of reinfectionFixed-dose combinationPost-treatment samplesRecurrent viremiaReinfection incidenceAgonist therapyDaily regimenHCV therapyHCV treatmentVirologic failureHCV GT1